Founded by Fortress Biotech, Helocyte is a clinical-stage biotechnology company developing immunotherapies for cancer and infectious diseases, with a particular focus on cytomegalovirus (CMV) complications in transplant recipients. Its lead Triplex vaccine is designed to generate a durable, virus-specific T-cell response and is being evaluated in multiple clinical trials, including studies involving stem-cell and liver-transplant patients. The company also has an option agreement with City of Hope covering a novel bispecific CMV/HIV CAR T-cell therapy.
CEL-SCI CorporationFormed in 1983, CEL-SCI Corporation is a biotechnology company conducting drug discovery, research, development, and manufacturing of complex biological substances. Its pipeline centers on investigational immune-based therapies, including Multikine, developed for potential use in cancer, and LEAPS candidates for autoimmune and infectious diseases. The company operates a dedicated manufacturing facility for investigational Multikine.ELKRIDGE, MD
Innovative Cellular TherapeuticsHeadquartered in Rockville, Innovative Cellular Therapeutics is a private clinical-stage biotechnology company developing cellular immunotherapies for solid tumors. Its proprietary CoupledCAR® platform underpins individually made CAR-T therapies, including the lead GCC19CART program being studied for relapsed or refractory metastatic colorectal cancer. Founded by Larry Lei Xiao and Zoe Zhao Wu, ICT combines more than 20 years of stem-cell, cell-therapy and gene-editing experience with FDA cellular-therapy review expertise.ROCKVILLE, MD
Medigen, IncMedigen, Inc. is a biomedical and vaccine company developing vaccines for emerging infectious diseases, chronic diseases including cancer, and other biopharmaceutical applications. Its explicitly described capabilities include vaccine manufacturing, cGMP production of cell and virus banks, virus and protein drug substance production, fill-finish, VLP design and production, molecular biology, electron microscopy, protein expression, and protein purification.FREDERICK, MD
STCubeSTCube is a Seoul-based biotechnology company developing precision immunotherapies for difficult-to-treat, resistant and recurrent cancers. Its central program is nelmastobart, described as the first anti-BTN1A1 immune-checkpoint inhibitor, developed through collaboration with institutions including MD Anderson Cancer Center. The company completed its first-in-human Phase 1 trial and is advancing biomarker-driven studies in colorectal and non-small-cell lung cancers.ROCKVILLE, MD